Turn Therapeutics Appoints Dr. Robert Redfield as Senior Advisor of Health Policy and Regulatory Affairs
Turn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare Conferences [Yahoo! Finance]
Turn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare Conferences
Turn Therapeutics (NASDAQ:TTRX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $8.00 price target on the stock.
Turn Therapeutics Announces Corporate and Pipeline Updates and 2026 Outlook Ahead of the 44th Annual J.P. Morgan Healthcare Conference